Some investors asked, Mr. Director, what is your company's layout in synthetic biology - gene therapy - cell therapy, etc.? Kanghong Pharmaceutical said on the interactive platform that in order to strengthen continuous innovation capabilities in new drug research and development, the company is based on key technical areas (biomedical industrialization technology, synthetic biological industrialization technology, standardized quality control technology for the entire proprietary Chinese medicine industry chain, novel formulation technology for solid oral drugs, green synthesis technology for chemical raw materials), and has established a research and development system including new drug research institutes, biopharmaceuticals research institutes, product technology centers, medical research centers, Hongji Biotech and Honghe Biotech's R&D system, and integrated superior resources at home and abroad. products It has achieved a certain leading edge in innovation and technological improvement. In terms of synthetic organisms, KH617 (glioblastoma) is advancing phase I clinical trials as planned. In the gene therapy sector, the gene therapy product KH631 (NaMD) will conduct phase II clinical trials as planned, and KH658 (NaMD) will enter phase I clinical trials.